Jon Ellis and Simon Vanstone, PhD, go behind the headlines to explore the latest M&A activity and what tariffs and funding changes could mean for mRNA and beyond.

Downstream processing for mRNA manufacturing is currently too complex, but simplifying by using precipitation looks promising.

In this week’s edition of InnovationRx, we look at the impact of Trump’s proposed budget cuts on biomedical research and ...

The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...

Moderna had already started a Phase 1/2 trial of its bird flu (H5N1) vaccine and reported strong early results.

Moderna (NASDAQ: MRNA) stock represented the ticket to an investing win. The company brought its coronavirus vaccine from ...

TriLink BioTechnologies & Quantoom Biosciences ink license and supply pact for CleanCap mRNA capping technology: San Diego Wednesday, June 4, 2025, 16:00 Hrs [IST] TriLink BioTech ...

Duke University says it's "an enormous setback" for creating a vaccine to fight the cause of AIDS. The Trump administration ...

Researchers have developed a new mRNA vaccine that overcomes the challenges associated with current mRNA therapeutic ...

The nationwide tally of COVID 19 cases have risen to 4,302. The fresh spike in number has come from Delhi, Uttar Pradesh, and ...

Amid a fresh wave of COVID-19, American researchers have now found a news type of mRNA vaccine to prevent the deadly disease.

A new type of mRNA vaccine is more scalable and adaptable to continuously evolving viruses such as SARS-CoV-2 and H5N1, according to a new study.